How should nephrologists approach gadolinium-based contrast imaging in patients with kidney disease?

Clinical Journal of the American Society of Nephrology

Volumn 3, Issue 3, 2008, Pages 649-651

  Perazella, Mark A ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONTRAST MEDIUM; GADODIAMIDE; GADOLINIUM PENTETATE; GADOTERIDOL; GADOVERSETAMIDE; HETEROCYCLIC COMPOUND; ORGANOMETALLIC COMPOUND;

CHEMICALLY INDUCED DISORDER; CHRONIC KIDNEY FAILURE; FIBROSIS; HUMAN; KIDNEY DISEASE; MAGNETIC RESONANCE ANGIOGRAPHY; NOTE; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PATIENT SELECTION; RENAL REPLACEMENT THERAPY; RISK ASSESSMENT; SKIN DISEASE; TIME;

CONTRAST MEDIA; FIBROSIS; GADOLINIUM DTPA; HETEROCYCLIC COMPOUNDS; HUMANS; KIDNEY DISEASES; KIDNEY FAILURE, CHRONIC; MAGNETIC RESONANCE ANGIOGRAPHY; MAGNETIC RESONANCE IMAGING; ORGANOMETALLIC COMPOUNDS; PATIENT SELECTION; RENAL DIALYSIS; RISK ASSESSMENT; SKIN DISEASES; TIME FACTORS;

EID: 44649192541     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.00670208     Document Type: Editorial

References (15)

1. Grobner T: Gadolinium: A specific trigger for the development of nephrogenic systemic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 21: 1104-1108, 2006
2. Rofsky NM, Weinreb JC, Bosniak MA, Libes RB, Birnbaum BA: Renal lesion characterization with gadolinium-enhanced MR imaging: Efficacy and safety in patients with renal insufficiency. Radiology 180: 85-89, 1991
3. Collidge TA, Thompson PC, Mark PB, Traynor JP, Jardine AG, Morris ST, Simpson K, Roditi GH: Gadolinium-enhanced MR imaging and nephrogenic systemic fibrosis: Retrospective study of a renal replacement therapy cohort. Radiology 245: 168-175, 2007
4. Marckmann P, Skov L, Rossen K, Dupont A, Damholt MB, Heaf JG, Thomsen HS: Nephrogenic systemic fibrosis: Suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol 17: 2359-2362, 2006
5. Deo A, Fogel M, Cowper SE: Nephrogenic systemic fibrosis: A population study examining the relationship of disease development to gadolinium exposure. Clin J Am Soc Nephrol 2: 264-267, 2007
6. Othersen J, Maize JC, Woolson RF, Budisavljevic MN: Nephrogenic systemic fibrosis after exposure to gadolinium in patients with renal failure. Nephrol Dial Transplant 22: 3179-3185, 2007
7. Todd DJ, Kagan A, Chibnik LB, Kay J: Cutaneous changes of nephrogenic systemic fibrosis: Predictor of early mortality and association with gadolinium exposure. Arthritis Rheum 56: 3433-3441, 2007
8. High WA, Ayers RA, Chandler J, Zito G, Cowper SE: Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol 56: 21-26, 2007
9. High WA, Eng M, Ayers RA, Cowper SE: Gadolinium is quantifiable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol 56: 1-2, 2007
10. Sieber MA, Pietsch H, Walter J, Haider W, Frenzel T, Weinmann HJ: A preclinical study to investigate the development of nephrogenic systemic fibrosis: A possible role for gadolinium-based contrast media. Invest Radiol 43: 65-75, 2008
11. Perazella MA: Tissue deposition of gadolinium and development of NSF: A convergence of factors. Semin Dial January 23, 2008 [Epub ahead of print]
12. United States Food and Drug Administration: Healthcare professional sheet: Gadolinium containing contrast agents for magnetic resonance imaging (MRI) (marketed as Omniscan®, OptiMARK®, Magnevist®, ProHance®, and MultiHance®. http://www.fda.gov/cder/drug /InfoSheets/HCP/gccaHCP.htm. Accessed February 7, 2008
13. Cowper SE: Nephrogenic Fibrosing Dermopathy [NFD/NSF Website]. 2001-2008. http://www.icnfdr.org. Accessed February 7, 2008
14. Ersoy H, Rybicki FJ: Biochemical safety profiles of gadolinium-based extracellular contrast agents and nephrogenic systemic fibrosis. J Magn Reson Imaging 26: 1190-1197, 2007
15. Dawson P, Punwani S: Nephrogenic systemic fibrosis: Non-gadolinium options for the imaging of CKD/ESRD patients. Semin Dial January 23, 2008 [Epub ahead of print]